A woman receives a mammogram from a physician. A woman receives a mammogram from a physician.

Veracyte’s approach to breast cancer treatment decision-making

About the journey to breast cancer treatment

Breast cancer is the most common cancer globally and one of the leading causes of cancer-related death in women.1,2 In 2020, there were an estimated 2.3 million new cases of breast cancer and approximately 685,000 deaths from the disease worldwide.3

Breast cancer treatment generally consists of three elements: Surgery to remove the tumor, radiotherapy to control the disease locally, and oral or intravenous medication to treat the cancer and reduce its risk of spreading.4 While breast cancer can return at any point after initial treatment, any breast cancer therapy to prevent recurrence can have side effects. Knowing an individual patient’s risk of disease recurrence can help clinicians and their patients select the most appropriate, personalized treatment approach.

Veracyte is using advanced molecular technology to provide this critical information.


new cases of breast cancer were diagnosed worldwide in 2020.3


deaths caused by breast cancer in 2020.3


Learn about our exceptional breast cancer diagnostics.

Identifying unmet needs through listening and collaboration

At Veracyte, we work closely with clinicians and researchers to understand how better testing technology could improve treatment decision-making for patients with breast cancer. The discovery of distinct molecular portraits enables researchers to define molecular subtypes of breast cancer, which can inform individual risk assessment to support personalized treatment. Veracyte developed the Prosigna test to apply these molecular subtypes, along with clinical factors, to the management of post-menopausal patients with early-stage HR+/human epidermal growth factor receptor 2 negative (HER2-) disease—the most prevalent kind of breast cancer.

Physicians and their patients with breast cancer must make important decisions about how best to treat the disease. Molecular testing that provides accurate prognostic information can help personalize treatment decision-making and improve patient outcomes.”

Professor, Genetics and Pathology & Laboratory Medicine

A smiling physician shows medical information to a patient.


Better prognostic information with the Prosigna® Breast Cancer Assay

Veracyte’s Prosigna Breast Cancer Assay is a genomic test designed to support more precise and timely treatment decisions for women with early-stage, HR+/HER2- breast cancer. The test analyzes the activity of 50 genes known as the PAM50 gene signature, combined with key clinical information, to provide a prognostic score. This score indicates the potential that an individual patient’s cancer will recur within the next 10 years. This information can help clinicians and their patients make more precise and timely treatment decisions. The Prosigna test also provides breast cancer molecular subtype information for the clinician’s additional reference.

A smiling older woman goes on a hike.

Learn about the Prosigna assay for breast cancer


  1. Cancer. World Health Organization. Published February 3, 2022. Accessed July 19, 2023. https://www.who.int/news-room/fact-sheets/detail/cancer

  2. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23. doi:10.1016/j.breast.2022.08.010

  3. Breast Cancer. World Health Organization. Published July 12, 2023. Accessed July 27, 2023. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

  4. Breast Cancer Treatment (PDQ®)–Health Professional Version. National Cancer Institute. Accessed July 27, 2023. https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

The Prosigna Breast Cancer Assay is FDA-cleared and CE-marked. For availability in individual EU countries and other territories outside of the US, please check with your local representative or distributor.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.